Skip to Content

NeuBase Therapeutics Inc NBSE

Morningstar Rating
$0.75 +0.03 (4.02%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

NBSE is trading at a 73% discount.
Price
$0.73
Fair Value
$6.12
Uncertainty
Extreme
1-Star Price
$35.67
5-Star Price
$5.76
Economic Moat
Glrd
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if NBSE is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$0.72
Day Range
$0.720.78
52-Week Range
$0.595.40
Bid/Ask
$0.75 / $0.78
Market Cap
$2.80 Mil
Volume/Avg
24,027 / 415,762

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

NeuBase Therapeutics Inc is a pre-clinical stage biopharmaceutical company. It is engaged in the development of gene silencing therapies with its synthetic antisense oligonucleotides. Its Patrol platform is focused on the development of drugs for rare genetic diseases such as Huntington's Disease, Myotonic Dystrophy and Familial Parkinson's Disease among others.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
37

Valuation

Metric
NBSE
Price/Earnings (Normalized)
Price/Book Value
0.27
Price/Sales
Price/Cash Flow
Price/Earnings
NBSE

Financial Strength

Metric
NBSE
Quick Ratio
2.70
Current Ratio
2.87
Interest Coverage
−2,824.19
Quick Ratio
NBSE

Profitability

Metric
NBSE
Return on Assets (Normalized)
−49.54%
Return on Equity (Normalized)
−78.42%
Return on Invested Capital (Normalized)
−60.13%
Return on Assets
NBSE
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRNpyc$537.7 Bil
VRTX
Vertex Pharmaceuticals IncWglhyh$108.4 Bil
REGN
Regeneron Pharmaceuticals IncWxwmr$104.6 Bil
MRNA
Moderna IncCxhr$33.4 Bil
ARGX
argenx SE ADRRrpv$23.7 Bil
BNTX
BioNTech SE ADRKjdq$22.0 Bil
ALNY
Alnylam Pharmaceuticals IncFsgzwf$19.5 Bil
BMRN
Biomarin Pharmaceutical IncSgmyn$16.7 Bil
RPRX
Royalty Pharma PLC Class AKsyzn$14.0 Bil
INCY
Incyte CorpBzzrbfc$13.5 Bil

Sponsor Center